S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ChemoCentryxProvention BioCymaBay TherapeuticsNeptune Wellness SolutionsMerus
SymbolNASDAQ:CCXINASDAQ:PRVBNASDAQ:CBAYNASDAQ:NEPTNASDAQ:MRUS
Price Information
Current Price$7.97$6.07$4.93$3.43$16.63
52 Week RangeBuyBuyBuyBuyBuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$18.33$20.25$14.00N/A$24.00
% Upside from Price Target130.03% upside233.61% upside183.98% upsideN/A44.32% upside
Trade Information
Market Cap$455.11 million$236.91 million$326.33 million$317.10 million$376.29 million
Beta1.155.791.321.840.24
Average Volume460,814428,987879,057904,06836,087
Sales & Book Value
Annual Revenue$42.88 millionN/A$10 million$18.39 million$37.14 million
Price / Sales10.79N/A33.8717.2410.19
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.29 per share$1.76 per share$2.87 per share$0.66 per share$4.77 per share
Price / Book27.48N/A1.725.203.49
Profitability
Net Income$-37,970,000.00$-26,480,000.00$-72,550,000.00$-17,670,000.00$-28,660,000.00
EPS($0.76)($1.19)($1.26)($0.14)($1.84)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/A11.06N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-144.27%N/AN/A-107.62%-104.10%
Return on Equity (ROE)-103.61%-64.53%-39.95%-23.18%-41.68%
Return on Assets (ROA)-23.08%-61.30%-37.09%-19.01%-16.58%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.28%N/A0.01%N/AN/A
Current Ratio3.57%8.43%16.20%1.21%5.94%
Quick Ratio3.57%8.43%16.20%0.82%5.94%
Ownership Information
Institutional Ownership Percentage64.24%5.62%98.60%11.84%52.00%
Insider Ownership Percentage12.20%19.60%4.20%N/AN/A
Miscellaneous
Employees7613435898
Shares Outstanding58.05 million39.35 million68.70 million92.45 million22.75 million
Next Earnings Date11/14/2019 (Estimated)11/14/2019 (Estimated)11/5/2019 (Estimated)11/12/2019 (Estimated)12/26/2019 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableNot Optionable
 ChemoCentryxProvention BioCymaBay TherapeuticsNeptune Wellness SolutionsMerus

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel